These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21047226)

  • 1. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF; Gilbert SM
    N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
    Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
    Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
    Chang SL; Liao JC; Shinghal R
    J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
    Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.
    Cetin K; Li S; Blaes AH; Stryker S; Liede A; Arneson TJ
    Urology; 2013 Jun; 81(6):1184-9. PubMed ID: 23601449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy.
    Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Chen LM; Hsieh CJ; Huang SP
    Clin Cancer Res; 2011 Feb; 17(4):928-36. PubMed ID: 21149617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D; Cowan J; Carroll P; Konety B
    BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
    BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
    Keating NL
    J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.